Press release
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:\n\n\n2023 RBC Capital Markets Global Healthcare Conference – May 17, 2023\n\n\nType: Fireside chat presentation\n\n\n91st European Atherosclerosis Society Congress – May 23, 2023\n\n\nType: Poster presentation\nTitle: ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum LDL-Cholesterol, Apolipoprotein B, and Angiopoietin-like Protein 3 in Patients with Homozygous Familial Hypercholesterolaemia\nWebcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\n\nAbout Arrowhead Pharmaceuticals\n\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.\n\n\nFor more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.\n\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\n\n\nThis news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of o...